Dr. Mandel Sher founded Sher Allergy Specialists out of a deep desire to make people feel better, whether they suffer from straightforward allergies and asthma, or complex medical problems that are yet to be solved. He has extensive training and researching in Allergy, Asthma and Immunology; Pediatrics; Adolescent Medicine; and Pediatric Rheumatology. In addition to leading Sher Allergy Specialists and the Center for Cough, Dr. Sher is a Clinical Professor at the University of South Florida Morsani College of Medicine and previously held the prestigious position of Chief Resident at Boston Children’s Hospital. He is a frequent program faculty for national professional society meetings, contributing author in peer-reviewed medical journals, and serves on committees and in leadership roles for professional societies. He has been honored by patients and peers with awards like “Best Doctor in America” and “Best Allergy and Immunology Specialist in Pinellas County.”

​

 MEDICAL SCHOOL 

• Northwestern University Feinberg School of Medicine

​

 RESIDENCY 

• Duke University Medical Center

• Boston Children’s Hospital

​

 FELLOWSHIPS 

• University of Michigan Medical Center

• Boston Children’s Hospital

​

 HONORS 

• Best Doctor in America

• Best Allergy and Immunology Specialist in Pinellas County

• US News & World Report

• Physician Extraordinaire at USF Morsani College of Medicine

• Patients’ feedback on exceptional care, service, and outcomes 

​

 BOARD CERTIFICATIONS 

• American Board of Allergy & Immunology

• American Board of Pediatrics

​

 PROFESSIONAL ACTIVITIES 

• Fellow of the American Academy of Allergy, Asthma, and Immunology

• Fellow of the American College of Allergy, Asthma, and Immunology

• Asthma Committee of the American College of Allergy, Asthma & Immunology

• Respiratory and Sleep-Related Breathing Disorders Committee of the American College of Allergy, Asthma & Immunology

• Asthma, Cough, Diagnosis and Treatment Committee of the American Academy of Allergy, Asthma & Immunology

​

 ACADEMIC TITLE 

• Clinical Professor of Medicine and Pediatrics, Division of Allergy and  Immunology, University of South Florida Morsani College of Medicine

​

 RECENT ABSTRACTS & PUBLICATIONS 

• Sher, Mandel R.; Steven, Gary C; Romett J. Lewis; Pien, Gary; LeBenger,Kerry; Messina, John C; Carothers, Jennifer L; Mahmoud, Ramy A.; Djupesland, Per G:   EXHANCE-3 cohort study of exhalation delivery system with fluticasone for chronic sinusitis with or without nasal polyps; Manuscript #19-124 ;  Rhinology J, Volume 58-Issue 1, 2020.

• Jaclyn A Smith, Michael M Kitt, Alyn H Morice, Surinder S. Birring, Lorcan P McGarvey, Mandel R Sher, Yu-Ping Li, Wen-Chi Wu, Zhi Jin Xu, David R Muccino, Anthony P Ford, Protocol 012 Investigators:  Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial,  Lancet Respir Med 2020 Feb 25;S2213-2600(19)30471-0.

• ·Jaclyn A Smith, Michael M Kitt, Peter Butera, Steven A Smith, Yuping Li, Zhi Jin Xu, Kimberly Holt, Shilpi Sen, Mandel R Sher, Anthony P Ford:  Gefapixant in two randomised dose-escalation studies in chronic cough,  Eur Respir J,  2020 Mar 20;55(3):1901615doi: 10.1183/13993003.01615-2019.

• Morice, AH, McGarvey, L,  Smith, JA, Sher, MR, Vaezi, Guilleminault, Niimi, and Dicpinigaitis,P: Phase IIb study design for BA 1817080 in the treatment of RCC. European Respiratory Society Congress, Vienna, 5-9 September 2020.

• Khan, Fatima, Ledford, Dennis K, Weston, Eric W, Sher, Mandel R.: An Unusual Presentation of Mast Cell Activation Syndrome and Pancreatic Neuroendocrine Tumor (PanNET).  American Academy of Allergy, Asthma & Immunology – 75th Annual Meeting, 2019.

• Sher MR, Birring S, Smith JA, McGarvey L, Morice A, Wu WC, Xu ZJ, Muccino DR. Evaluation of cough triggers among responders and non-responders of treatment with MK-7264, a P2X3 receptor antagonist. American Academy of Allergy, Asthma & Immunology - 75th Annual Meeting. 2019.

• Birring Surinder S;  S McGarvey, Lorcan; Smith, Jacyln A; Morice, Alyn H, Sher Mandel R; Wu, Wen-Chi; Xu, Zhi Jin; Nguyen Alison M; Schelfhout J; Muccino, David R. Baseline patient burden in chronic cough from a Phase 2b clinical trial of gefapixant, a P2X3 receptor antagonist. European Respiratory Society. September 2019.

• J. Smith, E. Ballantyne, M. Kerr, L. McGarvey, A. Morice, M. Sher, M. Trower, S. Pawsey.   The neurokinin-1 receptor antagonist orvepitant improves chronic cough symptoms: results from a Phase 2b trial.  European Respiratory Society – International Congress.  September 2019.

• Morice AH, Birring S, McGarvey L, Sher MR, Mehta A, Muccino DR Smith JA.   Consistency of improvement with gefapixant, a P2X3 receptor antagonist, in chronic cough patients during waking hours and over 24 hours.  CHEST Annual Meeting. October 2019. 

• Birring S, McGarvey L, Smith JA, Morice AH, Sher MR, Schelfhout J, Mehta A, Muccino DR. Benefits observed with patient-reported outcomes in a phase 2b clinical trial of gefapixant, a P2X3 receptor antagonist in chronic cough. CHEST Annual Meeting. October 2019.

​